Showing 31-40 of 187 results for "".
A Novel Therapeutic Option for the Treatment of Molluscum Contagiosum
https://practicaldermatology.com/topics/general-topics/a-novel-therapeutic-option-for-the-treatment-of-molluscum-contagiosum/21040/There is no FDA approved treatment for molluscum. A novel intervention may erradicate Molluscum with one treatment.Close Up With Lawrence Eichenfield, MD
https://practicaldermatology.com/topics/atopic-dermatitis/close-up-with-lawrence-eichenfield-md/24018/Back to the Future
https://practicaldermatology.com/topics/practice-management/back-to-the-future/23073/Dermatology and dermatologists will look a lot different in 20 years. Here’s a sneak peek.Clinical Case Report: Severe Allergic Contact Dermatitis of Eyelids: When Topical and Oral Steroids Are Not an Option
https://practicaldermatology.com/topics/general-topics/clinical-case-report-severe-allergic-contact-dermatitis-of-eyelids-when-topical-and-oral-steroids-are-not-an-option/21878/Topical calcineurin inhibitors may present a therapeutic option for contact dermatitis of the eyelids.Sunscreen Ratings, Long Live Skin Launches, SCALE Highlights
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-sunscreen-ratings-long-live-skin-launches-scale-highlights/18471/Consumer Reports says that one-third of sunscreens tested in its latest evaluation provided less than half of the SPF protection touted on the label. For its part, the American Academy of Dermatology is reminding patients that sunscreen ingredients are safe. The Environmental Working Group continuesPapa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouWell-Known “Novel” Therapeutic Option for Molluscum Contagiosum
https://practicaldermatology.com/topics/general-topics/well-known-novel-therapeutic-option-for-molluscum-contagiosum/20946/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20965/Rosacea Update: A Closer Look at Zilxi
https://practicaldermatology.com/columns/clinical-focus-1/rosacea-update-a-closer-look-at-zilxi/23339/Inside the approval of Zilxi for moderate-to-severe facial papulopustular rosacea.Topical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).